Veru (VERU)
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acu...
- Open
- 2.610
- High
- 2.630
- Low
- 2.571
- Prev. Close
- 2.630
- Volume
- 43.64K
- Turnover
- 113.61K
- Avg Price
- 2.604
- Bid/Ask Ratio
- 44.12%
- Amplitude
- 2.24%
- 52wk High
- 7.330
- Volume Ratio
- 0.53
- Turnover Ratio
- 0.32%
Veru Analyst Rating
View moreForecast & Rating
Jun 4, 2026Price forecast
$24.50849.61%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 19 hours ago
Veru Chief Scientific Officer Gary Barnette acquires $4,841.82 in common shares
- Motley Fool · 1 day ago, 06:41 AM
Veru (VERU) Q3 2026 Earnings Call Transcript
- Price Alert · Aug 11 at 05:13 AM
Pre-market hot trades in US stocks: Veru pre-market down 8.18%; USA Rare Earth pre-market down 7.20%
- Unusual Whales · Aug 10 at 06:08 AM
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
- PUBT · Aug 10 at 05:30 AM
Veru FY26 Q3 net loss narrows to $7 million; R&D expense rises 44% to $4.4 million
- TradingView · Aug 7 at 06:00 AM
VERU Q3'26 Earnings: EPS estimate is (0.32) USD
